|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 07/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Biomass Crop Assistance Program (BCAP) Funding
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
National Environmental Policy Act Requirements
Coexistence of Production Systems
EPA Regulations on Agricultural Biotechnology
Interior, Environment, and Related Agencies Appropriations Act for FY 2012
EPA Notice on PIP Data Requirements
Livestock Cloning/Product Labeling
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
FDA Approval
Labeling
Labeling of Genetically-Engineered Crops
U.S. Government Policy
TransPacific Partnership
Sanitary and Phytosanitary Issues
Foreign Agricultural Biotechnology Laws and Regulations
APEC Agricultural Biotechnology Discussions
Agricultural Trade Facilitation Act (Rep. Nunes Discussion Draft)
China Biotechnology Regulations
Discussions with EU on Animal Cloning
International Biotechnology Agreement
Korea Biotechnology Regulations
Regulatory Actions on Biological Pesticides
H.R. 872: Reducing Regulatory Burdens Act of 2011
Agricultural Biotechnology Regulatory Reform and Modernization
House Agriculture Subcommittee Hearing (June 2011)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE salmon
FDA Approval
Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Biomass Crop Assistance Program (BCAP) Funding
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
H.J. RES.48: Department of Defense and Continuing Appropriations Act for FY 2011
H.R. 1/H.J. RES.92: Continuing Appropriations Act for FY 2011
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R. 1/H.J. RES 92: Continuing Appropriations Act for FY 2011
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Funding for Bio-based Products
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
Funding for Biofuels
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
Funding for National Institutes of Health
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phyllis |
Arthur |
|
|
|
Ab |
Basu |
|
|
|
Matt |
Carr |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmettt |
|
|
|
Cartier |
Esham |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Sara |
Radcliffe |
|
|
|
Matthew |
Schumaker |
|
|
|
Sarah |
Thornton |
|
|
|
Anna |
Weinstein |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Climate Change Benefits
Regulatory Actions on Biological Pesticides
H.R. 872: Reducing Regulatory Burdens Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD), Air Force - Dept of, Navy - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
O'Brien |
|
|
|
Matt |
Carr |
|
|
|
Sarah |
Thornton |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
H.R. 1249: The Leahy-Smith America Invents Act of 2011
S. 23: The Patent Reform Act of 2011
World Trade Organization Special 301 Submissions
Russian Issues
PTO Administrative Reforms
DNA Patenting and Licensing
Rep. Wasserman Schultz Amendment to H.R. 1249: The Leahy-Smith America Invents Act of 2011
Intellectual Property International Enforcement
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), State - Dept of (DOS), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP), White House Office, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Hans |
Sauer |
|
|
|
Matthew |
Schumaker |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Dana |
O'Brien |
|
|
|
Roy |
Zwahlen |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
National Environmental Policy Act Requirements
Coexistence of Production Systems
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
FDA Approval
Labeling
Labeling of Genetically Engineered Crops
U.S. Government Policy
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R. 1/H.J. RES 92: Continuing Appropriations Act for FY 2011
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Drug Shortages
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Sandi |
Dennis |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Renewable Fuels Standard
Regulatory Oversight
Implementation of Energy Independence and Security Act of 2007
Biofuels
Next Generation Incentives: Farm Bill Reauthorization
Economic Growth Impact/Potential of Advanced Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Funding for Biofuels
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
Investment Tax Credit Options
Biofuels Production Tax Credit Extension
Domestic Manufacturing and Energy Jobs Act (Discussion Draft)
Biofuels Production Tax Credit Modification for Algae-based Biofuels
DOE Loan Guarantees and Grants under the Energy Policy Act of 2005 (Implementation and Funding)
Climate Change Benefits
Tax Credit
Bio-based Products
Expansion of DOE and USDA Loan Guarantee Programs
Tax Credit
Next Generation Incentives: Farm Bill Reauthorization
Funding for Bio-based Products
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
USDA BioPreferred Program
Renewable Chemicals
Farm Bill Reauthorization: DOE Loan Guarantees
S.847: The Safe Chemicals Act of 2011 (TSCA Reform Proposals)
New Production Tax Credit/Revisions to Existing Tax Credits
17. House(s) of Congress and Federal agencies Check if None
Environmental Protection Agency (EPA), U.S. HOUSE OF REPRESENTATIVES, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, U.S. SENATE, White House Office, Air Force - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
Schumaker |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Labeling of Genetically Engineered Crops
U.S. Government Policy
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
FDA Approval
Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Renewable Fuels Standard
Regulatory Oversight
Implementation of Energy Independence and Security Act of 2007
Biofuels
Next Generation Incentives: Farm Bill Reauthorization
Economic Growth Impact/Potential of Advanced Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Funding for Biofuels
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
Investment Tax Credit Options
Biofuels Production Tax Credit Extension
Domestic Manufacturing and Energy Jobs Act (Discussion Draft)
Biofuels Production Tax Credit Modification for Algae-based Biofuels
DOE Loan Guarantees and Grants under the Energy Policy Act of 2005 (Implementation and Funding)
Climate Change Benefits
Tax Credit
Bio-based Products
Expansion of DOE and USDA Loan Guarantee Programs
Tax Credit
Next Generation Incentives: Farm Bill Reauthorization
Funding for Bio-based Products
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
USDA BioPreferred Program
Renewable Chemicals
Farm Bill Reauthorization: DOE Loan Guarantees
S.847: The Safe Chemicals Act of 2011 (TSCA Reform Proposals)
New Production Tax Credit/Revisions to Existing Tax Credits
17. House(s) of Congress and Federal agencies Check if None
Environmental Protection Agency (EPA), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, Air Force - Dept of, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
Schumaker |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Medicare Prescription Drug Coverage
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Biosimilars
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Funding for National Institutes of Health
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
Vaccine Access/Financing
S. 1094: Combating Autism Reauthorization Act
Expansion of 340B Drug Pricing Program
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Medicaid Rebates
Dual Eligibles
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Diagnostics and Personalized Medicine Regulation and Oversight
Therapeutic Discovery Project Tax Credit
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Extension
Rare Pediatric & Tropical Disease Drug Development
Drug Safety and Review
Regulatory Reforms for Innovative Products
Prescription Drug User Fee Act (PDUFA) Reauthorization
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R. 1/H.J. RES 92: Continuing Appropriations Act for FY 2011
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Independent Payment Advisory Board
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Repeal
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
H.J. RES.48: Department of Defense and Further Additional Continuing Appropriations Act for FY 2011
H.R. 1/H.J. RES.92: Continuing Appropriations Act for FY 2011
Cures Acceleration Network
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Biodefense Research, Development and Procurement
HHS Countermeasures Review
Pandemic and All-Hazards Preparedness Act Reauthorization
Drug Shortages
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuticals
Reimbursement for Innovative Products
Medicare Policies and Regulation
17. House(s) of Congress and Federal agencies Check if None
Internal Revenue Service (IRS), Treasury - Dept of, U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), State - Dept of (DOS), White House Office, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelly |
Mui-Lipnik |
|
|
|
Roy |
Zwahlen |
|
|
|
Sandi |
Dennis |
|
|
|
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Cartier |
Esham |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Brent |
DelMonte |
|
|
|
Alan |
Eisenberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement
HHS Countermeasures Review
Pandemic and All-Hazards Preparedness Act Reauthorization
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
H.J. RES.48: Department of Defense and Further Additional Continuing Appropriations Act for FY 2011
H.R. 1/H.J. RES.92: Continuing Appropriations Act for FY 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
Anna |
Weinstein |
|
|
|
Phyllis |
Arthur |
|
|
|
Matthew |
Schumaker |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Cures Acceleration Network
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Funding for National Institutes of Health
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
Rare Pediatric & Tropical Disease Drug Development
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2012
H.J. RES. 48: Department of Defense and Further Additional Continuing Appropriations Act for FY 2011
H.R. 1/H.J. RES.92: Continuing Appropriations Act for FY 2011
Biodefense Research, Development and Procurement
HHS Countermeasures Review
Pandemic and All-Hazards Preparedness Act Reauthorization
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tracey |
LaTurner |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Phyllis |
Arthur |
|
|
|
Cartier |
Esham |
|
|
|
Sara |
Radcliffe |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Reimbursement for Innovative Products
Medicare Policies and Regulation
Medicare Prescription Drug Coverage
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Medicaid Rebates
Dual Eligibles
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Independent Payment Advisory Board
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Repeal
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Melissa |
Bowie |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Laurel |
Todd |
|
|
|
Sandi |
Dennis |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Research & Development Tax Credit Extension
H.R. 942: American Research and Competitiveness Act of 2011
Small Business Innovation and Research (SBIR) Program Reauthorization
S.493: SBIR/STTR Reauthorization Act of 2011
HR 1425: Creating Jobs Through Small Business Innovation Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Matthew |
Schumaker |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
DelMonte |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Investment Incentives
Sarbanes Oxley Section 404 (b) Exemption
Small Business Innovation and Research (SBIR) Program Reauthorization
S.493: SBIR/STTR Reauthorization Act of 2011
HR 1425: Creating Jobs Through Small Business Innovation Act of 2011
Therapeutic Discovery Project Tax Credit
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Extension
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Internal Revenue Service (IRS), Treasury - Dept of, Securities & Exchange Commission (SEC), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Melissa |
Bowie |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tooshar |
Swain |
|
|
|
Anna |
Weinstein |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Bio-based Products
Tax Credit
Election of R&D/AMT Tax Credits in Lieu of Bonus Depreciation
Therapeutic Discovery Project Tax Credit
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Extension
Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Biofuels Production Tax Credit Extension
Investment Tax Credit Options
Research & Development Tax Credit Extension
H.R. 942: American Research and Competitiveness Act of 2011
Capital Formation Investment Incentives
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Internal Revenue Service (IRS), Treasury - Dept of, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
Schumaker |
|
|
|
Rina |
Singh |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Sarah |
Thornton |
|
|
|
Cartier |
Esham |
|
|
|
Tooshar |
Swain |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
World Trade Organization Special 301 Submissions
Russian Issues
Livestock Cloning/Product Labeling
Intellectual Property International Enforcement
TransPacific Partnership
Sanitary and Phytosanitary Issues
Data and Intellectual Property Protection for Pharmaceuticals
Foreign Agricultural Biotechnology Laws and Regulations
Agricultural Trade Facilitation Act (Rep. Nunes Discussion Draft)
Discussions with EU on Animal Cloning
Korea Biotechnology Regulations
China Biotechnology Regulations
International Biotechnology Agreement
APEC Agricultural Biotechnology Discussions
Labeling of Genetically Engineered Crops
U.S. Government Policy
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), State - Dept of (DOS), Commerce - Dept of (DOC), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
David |
Edwards |
|
|
|
Matthew |
Schumaker |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Roy |
Zwahlen |
|
|
|
Matthew |
O'Mara |
|
|
|
Dana |
O'Brien |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Medicare Prescription Drug Coverage
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Medicaid Rebates
Dual Eligibles
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Drug Shortages
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Anna |
Weinstein |
|
|
|
Sandi |
Dennis |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |